Incontinence in myelodysplasia: imipramine hydrochloride revisited.
Hurley
R M
RM
Department of Pediatrics, University of Western Ontario, London, Canada.
Harris
D
D
Shepherd
R R
RR
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009436:Neural Tube Defects / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology
D018759:Adrenergic Uptake Inhibitors; D000929:Antidepressive Agents, Tricyclic; D007099:Imipramine